Mankind Pharma Ltd. - Research Center
543904 MANKIND Group (B) BSE data
Add to watchlist
| Results | |
| Statement |
P&L
|
| More |
Profit loss account
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Income | |||||
| Operating income | 8,127.15 | 7,257.04 | 5,529.60 | 4,794.41 | 3,877.49 |
| Expenses | |||||
| Material consumed | 2,888.57 | 2,477.79 | 1,821.61 | 1,612.86 | 1,382.96 |
| Manufacturing expenses | 62.00 | 59.73 | 47.16 | 46.49 | 35.07 |
| Personnel expenses | 1,701.38 | 1,443.83 | 1,106.14 | 991.47 | 785.02 |
| Selling expenses | 385.85 | 441.38 | 387.87 | 208.09 | 337.40 |
| Adminstrative expenses | 1,391.97 | 1,034.69 | 788.54 | 692.05 | 632.64 |
| Expenses capitalised | - | - | - | - | - |
| Cost of sales | 6,429.77 | 5,457.42 | 4,151.31 | 3,550.96 | 3,173.09 |
| Operating profit | 1,697.38 | 1,799.61 | 1,378.29 | 1,243.46 | 704.40 |
| Other recurring income | 162.78 | 162.73 | 148.08 | 93.85 | 64.33 |
| Adjusted PBDIT | 1,860.16 | 1,962.34 | 1,526.37 | 1,337.31 | 768.73 |
| Financial expenses | 27.75 | 43.83 | 7.98 | 10.62 | 39.04 |
| Depreciation | 269.58 | 120.98 | 78.19 | 61.77 | 38.39 |
| Other write offs | - | - | - | - | - |
| Adjusted PBT | 1,562.84 | 1,797.54 | 1,440.21 | 1,264.92 | 691.30 |
| Tax charges | 314.58 | 462.41 | 355.83 | 306.70 | 177.26 |
| Adjusted PAT | 1,248.26 | 1,335.13 | 1,084.37 | 958.23 | 514.04 |
| Non recurring items | -4.86 | -0.63 | -1.56 | -7.33 | -1.64 |
| Other non cash adjustments | - | - | - | - | - |
| Reported net profit | 1,243.40 | 1,334.50 | 1,082.82 | 950.90 | 512.39 |
| Earnigs before appropriation | 7,868.30 | 6,164.45 | 4,829.95 | 4,111.40 | 3,189.42 |
| Equity dividend | - | - | - | 240.62 | 19.14 |
| Preference dividend | - | - | - | - | - |
| Dividend tax | - | - | - | 61.82 | 4.89 |
| Retained earnings | 7,868.30 | 6,164.45 | 4,829.95 | 3,808.95 | 3,165.39 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis